Both anti-PD-1 and -PD-L1 induce response rates of 19% in patients with heavily pre-treated, chemotherapy-resistant, PD-L1-positive, triple-negative breast cancers (TNBCs) [7]. The gene discussed is CD274; the disease is triple-negative breast carcinoma.